CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy.
Hara A, Koyama-Nasu R, Takami M, Toyoda T, Aoki T, Ihara F, Kobayashi M, Hirono S, Matsutani T, Nakayama T, Iwadate Y, Motohashi S.
Hara A, et al. Among authors: ihara f.
Cancer Immunol Immunother. 2021 May;70(5):1239-1254. doi: 10.1007/s00262-020-02742-1. Epub 2020 Oct 31.
Cancer Immunol Immunother. 2021.
PMID: 33128583
Free PMC article.